from 6-K, 1 October 2002.......
5. Other investments
BioInvent
International
AB
GBP'000
______NeoGenesis
Pharmaceuticals
Inc
GBP'000
______
Total
GBP'000
______
Cost:
At 1 January 2002 -4,2514,251
Additions 3,528-3,528
At 30 June 20023,5284,2517,779
Provisions:
At 1 January 2002 and 30 June 2002---
Net book value:
At 30 June 20023,5284,2517,779
Net book value:
At 31 December 2001-4,2514,251
On 16 May 2002, OGS subscribed SEK52.0 million in cash at
SEK39.1 per share in
BioInvent International AB, as part of a research
collaboration.
At 30 June 2002, BioInvent International AB's share price was
SEK28.5 per share.
However, this investment, and the investment in NeoGenesis
Pharmaceuticals Inc,
is not held for resale and management do not consider that any
permanent
diminution in value existed at that date.
(I can't translate.... anybody else? Is the value of their NeoG holding hidden in there, someplace?) |
